Corticosteroids Treatment of Patients with Coronavirus Disease 2019: A Propensity Score Matching Study

Abstract

The role of corticosteroids in the treatment of Coronavirus disease 2019 (COVID-19) is controversial. In the present study, we evaluated the effects of adjuvant corticosteroids treatment on the outcome of patients with COVID-19 (n=966), using Propensity Score Matching to adjust for potential differences between the corticosteroids group (n=289) and the non-corticosteroids group (n=677). Analysis of data without adjusting differences in baseline characteristics indicated that the proportion of mechanical ventilation and the mortality was higher in the corticosteroids treatment group in total or severe/critical patients. The duration of viral shedding was longer in the non-corticosteroids treatment group in total or general/mild patients. After adjusting the difference between the corticosteroids and non-corticosteroids treatment group, the analysis revealed that the use of corticosteroids had no effect on the duration of viral shedding, in-hospital mortality or 28-day mortality.

Keywords

severe acute respiratory syndrome coronavirus 2 / coronavirus disease 2019 / corticosteroids / mortality / viral shedding

References

[1] PhelanAL, KatzR, GostinLO. The Novel Coronavirus Originating in Wuhan, China: Challenges for Global Health Governance. JAMA, 2020, 323(8): 709-710

[2] KickbuschI, LeungG. Response to the emerging novel coronavirus outbreak. BMJ, 2020, 368: m406

[3] ChannappanavarR, PerlmanS. Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology. Semin Immunopathol, 2017, 39(5): 529-539

[4] ZhouJ, ChuH, LiC, et al.. Active MERS-CoV replication and aberrant induction of inflammatory cytokines and chemokines in human macrophages: implications for pathogenesis. J Infect Dis, 2014, 209(9): 1331-1342

[5] YeQ, WangB, MaoJ. The pathogenesis and treatment of the “Cytokine Storm” in COVID-19. J Infect, 2020, 80(6): 607-613

[6] Brun-BuissonC, RichardJC, MercatAREVA-SRLF A/H1N1v 2009 Registry Group, et al.. Early corticosteroids in severe influenza A/H1N1 pneumonia and acute respiratory distress syndrome. Am J Respir Crit Care Med, 2011, 183(9): 1200-1206

[7] Martin-LoechesI, LisboaT, RhodesA, et al.. Use of early corticosteroid therapy on ICU admission in patients affected by severe pandemic (H1N1)v influenza A infection. Intensive Care Med, 2011, 37(2): 272-283

[8] LeeN, LeoYS, CaoB, et al.. Neuraminidase inhibitors, superinfection and corticosteroids affect survival of influenza patients. Eur Respir J, 2015, 45(6): 1642-1652

[9] ChenRC, TangXP, TanSY, et al.. Treatment of severe acute respiratory syndrome with glucosteroids: the Guangzhou experience. Chest, 2006, 129(6): 1441-1452

[10] AuyeungTW, LeeJS, LaiWK, et al.. The use of corticosteroid as treatment in SARS was associated with adverse outcomes: a retrospective cohort study. J Infect, 2005, 51(2): 98-102

[11] YamLY, LauAC, LaiFY, et al.. Hong Kong Hospital Authority SARS Collaborative Group (HASCOG). Corticosteroid treatment of severe acute respiratory syndrome in Hong Kong. J Infect, 2007, 54(1): 28-39

[12] ArabiYM, MandourahY, Al-HameedFSaudi Critical Care Trial Group, et al.. Corticosteroid Therapy for Critically Ill Patients with Middle East Respiratory Syndrome. Am J Respir Crit Care Med, 2018, 197(6): 757-767

[13] RussellCD, MillarJE, BaillieJK. Clinical evidence does not support corticosteroids treatment for 2019-nCoV lung injury. Lancet, 2020, 395(10223): 473-475

[14] LiuJ, ZhangS, DongX, et al.. Corticosteroid treatment in severe COVID-19 patients with acute respiratory distress syndrome. J Clin Invest, 2020, 130(12): 6417-6428

[15] ShangL, ZhaoJ, HuY, et al.. On the use of corticosteroids for 2019-nCoV pneumonia. Lancet, 2020, 395(10225): 683-684

[16] RECOVERY Collaborative Group, Horby P, Lim WS, et al. Dexamethasone in Hospitalized Patients with Covid-19 - Preliminary Report. N Engl J Med, 2020, NEJMoa2021436

[17] National Health Commission of the People’s Republic of China. Diagnosis and Treatment Program of New Coronary Pneumonia (the seventh edition). 2020, Accessed 3 March 2020. Available from:http://www.nhc.gov.cn/yzygj/s7653p/202003/46c9294a7dfe4cef80dc7f5912eb1989.shtml [Google Scholar]

[18] WongCK, LamCW, WuAK, et al.. Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome. Clin Exp Immunol, 2004, 136(1): 95-103

[19] MahallawiWH, KhabourOF, ZhangQ, et al.. MERS-CoV infection in humans is associated with a proinflammatory Th1 and Th17 cytokine profile. Cytokine, 2018, 104: 8-13

[20] CraddockCG. Corticosteroid-induced lymphopenia, immunosuppression, and body defense. Ann Intern Med, 1978, 88(4): 564-566

[21] LiuZ, LiX, FanG, et al.. Low-to-moderate dose corticosteroids treatment in hospitalized adults with COVID-19. Clin Microbiol Infect, 2021, 27(1): 112-117

[22] ZhaL, LiS, PanL, et al.. Corticosteroid treatment of patients with coronavirus disease 2019 (COVID-19). Med J Aust, 2020, 212(9): 416-420

[23] Martin-LoechesI, LisboaT, RhodesA, et al.. Use of early corticosteroids therapy on ICU admission in patients affected by severe pandemic (H1N1)v influenza A infection. Intensive Care Med, 2011, 37(2): 272-283

[24] NiYN, ChenG, SunJ, et al.. The effect of corticosteroids on mortality of patients with influenza pneumonia: a systematic review and meta-analysis. Crit Care, 2019, 23(1): 99

[25] HanK, MaH, AnX, et al.. Early Use of corticosteroids Was a Risk Factor for Critical Disease and Death From pH1N1 Infection. Clin Infect Dis, 2011, 53(4): 326-333

[26] LeeFE, WalshEE, FalseyAR. The Effect of Steroid Use in Hospitalized Adults With Respiratory Syncytial Virus-Related Illness. Chest, 2011, 140(5): 1155-1161

[27] LeeN, ChanKCA, HuiDS, et al.. Effects of early corticosteroids treatment on plasma SARS-associated Coronavirus RNA concentrations in adult patients. J Clin Virol, 2004, 31(4): 304-309